RNA, U1 small nuclear 83, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-83P profile across patient tissues and cancer cell-line models. RNU1-83P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU1-83P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RNU1-83P RNA expression shows 5,794 significant pathway-activity associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, BRCA, and ESCA as cancer lineages where RNU1-83P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-83P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-83P survival associations across molecular data types. RNU1-83P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-83P RNA expression–survival associations across cancer types. High RNU1-83P expression shows unfavorable associations in HNSC, UCS, LIHC, UVM, KICH and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU1-83P RNA expression.
This table summarizes RNU1-83P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-83P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-83P shows higher tumor expression in BRCA, PRAD, LUAD, KIRP and COAD. The BRCA box plot shows higher RNU1-83P RNA expression in tumor versus normal tissue (log2 FC = +0.227, t-test p = .040).
This table shows molecular features associated with RNU1-83P in patient tissues and cancer cell lines. In patient samples, RNU1-83P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
